• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom sales climb 30% in Q1, beating estimates on The Street

May 3, 2018 By Sarah Faulkner

DexcomDexcom (NSDQ:DXCM) beat expectations on Wall Street yesterday with its first-quarter results, topping analysts’ sales estimates by $12.3 million.

The San Diego, Calif.-based company posted a net loss of -$24.2 million, or -28¢, on sales of $184.4 million for the three months ended March 31, for bottom-line growth of 42% on sales growth of 30% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -32¢, a penny ahead of consensus on The Street, where analysts were looking for sales of $172.1 million.

“Dexcom is off to a solid start in 2018. Revenue growth remained strong in Q1, carrying the momentum we saw exiting last year, and the company demonstrated good expense control,” president & CEO Kevin Sayer said in prepared remarks.

Dexcom said it expects to post sales of $850 million to $860 million for the full year, up from the prior range of $830 million to $850 million.

DXCM shares were trading at $78.00 apiece today in premarket activity, up 5%.

In March, Dexcom won FDA approval for its latest continuous glucose monitor. The G6 system is the first of the company’s that does not require a finger-prick for calibration and is also cleared as “fully interoperable” with other medical devices, like insulin pumps and decision support software.

“This Gen 6 system brings to fruition all that I envisioned when I first saw a sensor in the 90’s,” Sayer told Drug Delivery Business News. 

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Pharmaceuticals, Wall Street Beat Tagged With: DexCom Inc.

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS